Laidlaw Reiterates Buy Rating on Ionis Pharmaceuticals (IONS) After Phase 3 Launch
Tweet Send to a Friend
Laidlaw analyst Yale Jen reiterated a Buy rating and $78.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
